Table 8.
Results of serologic and parasitological assays at baseline (T0) and at two follow-up determinations (T3 and T6) in dogs treated for CanLa
| Time (no. of animals) | No. of positive dogs (%, 95% CI) |
||||
|---|---|---|---|---|---|
| Clinical signs | IFAT | LN-CE | BC n-PCR | CS n-PCR | |
| T0 (20) | 20 (100, 83.2–100) | 20 (100, 83.2–100) | 17 (85, 62.1–96.8) | 9 (45, 23.1–68.5) | 20 (100, 83.2–100) |
| T3 (20) | 0 (0, 0–16.84) | 20 (100, 83.2–100) | 2 (10, 27.2–72.8) | 1 (5, 0.1–24.9) | 6 (30, 11.9–54.3) |
| T6 (18) | 0 (0, 0–19.5) | 18 (100, 83.2–100) | 4 (22.22, 14.3–31.4) | 8 (44.44, 34.1–54.3) | 16 (88.89, 77.18–99.5) |
a
IFAT, indirect immunofluorescence antibody test; LN-CE, cytological examination of lymph node aspirate; BC n-PCR, n-PCR on buffy coat from peripheral blood; CS n-PCR, n-PCR on conjunctival swab; T0, before treatment; T3, 3 months from treatment onset; T6, 6 months from treatment onset.